Health Care & Life Sciences » Pharmaceuticals | Beijing Beilu Pharmaceutical Co. Ltd.

Beijing Beilu Pharmaceutical Co. Ltd. | Cash Flow

Fiscal year is January-December. All values CNY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
65,971.70
94,164.70
30,916.10
15,505.10
118,816.70
147,761.90
Depreciation, Depletion & Amortization
8,481.30
13,009.80
21,569.40
21,119.70
17,167.90
17,384.10
Other Funds
-
20,633.30
246,000.00
693.80
19.30
6,449.30
Funds from Operations
73,647.80
110,766.70
117,255.70
104,239.50
124,999.20
169,128.90
Changes in Working Capital
32,277.80
68,891.90
40,430.10
27,174.80
22,964.00
9,510.40
Net Operating Cash Flow
41,370.00
41,874.80
76,825.70
77,064.70
147,963.20
178,639.30
Capital Expenditures
35,480.50
42,985.70
69,233.80
44,206.50
54,995.90
Sale of Fixed Assets & Businesses
2,933.00
-
125.80
536.60
21.60
Purchase/Sale of Investments
-
33,865.20
4,000.00
153,150.00
5,553.30
Net Investing Cash Flow
32,547.50
181,716.00
153,108.00
204,599.30
5,527.60
Cash Dividends Paid - Total
30,549.80
31,119.50
18,395.90
6,519.90
3,259.50
Issuance/Reduction of Debt, Net
-
50,055.40
28,156.10
31,899.30
-
Net Financing Cash Flow
30,549.80
39,569.20
199,424.00
54,615.50
3,240.20
Net Change in Cash
21,727.30
100,272.00
123,141.70
182,150.10
139,195.30
Free Cash Flow
5,889.50
1,110.90
7,591.90
32,858.20
92,967.30
Deferred Taxes & Investment Tax Credit
230.00
290.00
863.70
11,580.70
1,314.40
10,432.20
Net Assets from Acquisitions
-
104,865.10
80,000.00
-
-
Other Sources
-
-
-
-
195,000.00
Change in Capital Stock
-
-
23.90
15,502.60
-
Other Uses
-
-
-
7,779.30
140,000.00

About Beijing Beilu Pharmaceutical Co.

View Profile
Address
7/F, Blk A, Fenglan Intl Office Bldg
Beijing Beijing 100082
China
Employees -
Website http://www.beilu.com.cn
Updated 07/08/2019
Beijing Beilu Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical product. Its products cover contrast medium product, glimepiride, and anti-anxiety product. The contrast medium product includes ferric ammonium citrate, gadopentetate, and iohexol injection.